Hwail Pharm Co Ltd
KOSDAQ:061250
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| KR |
H
|
Hwail Pharm Co Ltd
KOSDAQ:061250
|
90.6B KRW |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
979.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
590.5B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
298.2B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
240.7B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
247.5B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
306.4B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.2B USD |
Loading...
|
Market Distribution
| Min | -646.5% |
| 30th Percentile | 12.8% |
| Median | 19.7% |
| 70th Percentile | 32.2% |
| Max | 54 001.3% |
Other Profitability Ratios
Hwail Pharm Co Ltd
Glance View
HWAIL PHARMACEUTICAL Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do and currently employs 149 full-time employees. The company went IPO on 2002-04-18. The firm produces aceclofenac, lornoxicam, triflusal, dicloalphenazone, gallamine triethyl iodide, acemetacin, levosulpiride, alibendol, erdostein, talniflumate, topiramate, phloroglucin, oxatomide and others used as expectorants, cough remedies, antispasmodics, analgesics, anti-inflammatories and others under the brand name EDST, TRPR, LVSP, ACCL and others. The company also provides finished formulations, including injection products such as ceftazidime, cefoperazone, cefotaxime, cefaclor, cefatrizine, cefroxadine and others. The firm distributes its products within domestic market and to overseas markets.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Hwail Pharm Co Ltd is 7.9%, which is below its 3-year median of 8.7%.
Over the last 3 years, Hwail Pharm Co Ltd’s Gross Margin has decreased from 11.4% to 7.9%. During this period, it reached a low of 7.9% on Jun 30, 2025 and a high of 11.4% on Sep 30, 2022.
